NO931766L - Topiske preparater for transdermal avlevering av forloeperlegemiddelderivater av morfin - Google Patents

Topiske preparater for transdermal avlevering av forloeperlegemiddelderivater av morfin

Info

Publication number
NO931766L
NO931766L NO93931766A NO931766A NO931766L NO 931766 L NO931766 L NO 931766L NO 93931766 A NO93931766 A NO 93931766A NO 931766 A NO931766 A NO 931766A NO 931766 L NO931766 L NO 931766L
Authority
NO
Norway
Prior art keywords
morphine
transdermal delivery
preservant
pct
topical preparations
Prior art date
Application number
NO93931766A
Other languages
English (en)
Norwegian (no)
Other versions
NO931766D0 (no
Inventor
Hans Bundgaard
Lona Christrup
Joern Drustrup
Ann Fullerton
Martin Nicklasson
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Publication of NO931766D0 publication Critical patent/NO931766D0/no
Publication of NO931766L publication Critical patent/NO931766L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO93931766A 1990-11-16 1993-05-14 Topiske preparater for transdermal avlevering av forloeperlegemiddelderivater av morfin NO931766L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9003665A SE9003665D0 (sv) 1990-11-16 1990-11-16 Morphine prodrugs
PCT/SE1991/000760 WO1992008459A1 (en) 1990-11-16 1991-11-11 Topical compositions for transdermal delivery of produg derivatives of morphine

Publications (2)

Publication Number Publication Date
NO931766D0 NO931766D0 (no) 1993-05-14
NO931766L true NO931766L (no) 1993-05-14

Family

ID=20380936

Family Applications (1)

Application Number Title Priority Date Filing Date
NO93931766A NO931766L (no) 1990-11-16 1993-05-14 Topiske preparater for transdermal avlevering av forloeperlegemiddelderivater av morfin

Country Status (18)

Country Link
US (1) US5908846A (fi)
EP (1) EP0557385B1 (fi)
JP (1) JP3493434B2 (fi)
AT (1) ATE168560T1 (fi)
AU (1) AU655612B2 (fi)
CA (1) CA2095223C (fi)
DE (1) DE69129861T2 (fi)
DK (1) DK0557385T3 (fi)
ES (1) ES2121793T3 (fi)
FI (1) FI932212A0 (fi)
IE (1) IE913682A1 (fi)
IL (1) IL99905A (fi)
NO (1) NO931766L (fi)
NZ (1) NZ240349A (fi)
PT (1) PT99513B (fi)
SE (1) SE9003665D0 (fi)
WO (1) WO1992008459A1 (fi)
ZA (1) ZA918512B (fi)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
DE4403709A1 (de) * 1994-02-07 1995-08-10 Lohmann Therapie Syst Lts Pharmazeutische Zusammensetzung zur systemischen transdermalen Verabreichung mit dem Wirkstoff Morphin-6-glucuronid
JPH07267862A (ja) * 1994-03-29 1995-10-17 Sekisui Chem Co Ltd 経皮吸収貼付剤
WO1996028451A1 (en) * 1995-03-14 1996-09-19 Euroceltique S.A. Morphine-3-esters
DE19508664C2 (de) * 1995-03-14 2001-08-23 Christian Mignat Verwendung von Morphin-3-estern, Morphin-3-ester als solche und Verfahren zu deren Herstellung
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
DE19602963A1 (de) * 1995-12-20 1997-07-31 Nycomed Arzneimittel Gmbh Neue Morphinderivate, Verfahren zu deren Herstellung und deren Verwendung
DE19923551A1 (de) * 1999-05-21 2000-11-30 Lohmann Therapie Syst Lts Pharmazeutisches Präparat mit dem Wirkstoff Diamorphin und seine Verwendung in einem Verfahren zur Behandlung der Opiatsucht
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
BRPI0015284B8 (pt) 1999-10-29 2021-05-25 Euro Celtique S/A formulações de hidrocodona de liberação controlada
US20020013331A1 (en) * 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
KR101045144B1 (ko) 2000-10-30 2011-06-30 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US6569449B1 (en) * 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
CN1262274C (zh) * 2000-11-14 2006-07-05 生命健康科学有限公司 磷酸盐衍生物复合物
AUPR549901A0 (en) * 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
US20030022876A1 (en) * 2001-06-05 2003-01-30 Ashton Paul A. Sustained-release analgesic compounds
MXPA04000654A (es) * 2001-07-27 2004-03-19 Vital Health Sciences Pty Ltd Terapia dermica usando derivados de fosfato de agente de transferencia de electrones.
CA2466536C (en) * 2001-12-13 2012-02-07 Vital Health Sciences Pty Ltd Transdermal transport of compounds
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
DE60329515D1 (de) * 2002-10-25 2009-11-12 Euro Celtique Sa Analoga und prodrugs von buprenorphin
WO2004043396A2 (en) * 2002-11-09 2004-05-27 Nobex Corporation Modified carbamate-containing prodrugs and methods of synthesizing same
ATE534384T1 (de) * 2003-01-17 2011-12-15 Vital Health Sciences Pty Ltd Verbindungen mit proliferationshemmenden eigenschaften
AU2003901815A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphate derivatives
CA2529983C (en) * 2003-07-25 2010-07-20 Bruce E. Reidenberg Preoperative treatment of post operative pain
ES2338054T3 (es) 2004-02-06 2010-05-03 Euro-Celtique S.A. Metodos para producir morfinonas 3-o-protegidas y carboxilatos de morfinona dienol 3-o-protegidos.
ES2447547T3 (es) 2004-02-23 2014-03-12 Euro-Celtique S.A. Dispositivo de administración transdérmica de opioides con resistencia al abuso
DE602005025979D1 (de) 2004-03-03 2011-03-03 Vital Health Sciences Pty Ltd Alkaloid-formulierungen
EP1893159B1 (en) 2005-06-17 2015-09-30 Vital Health Sciences Pty Ltd. A carrier comprising one or more di- and/or monophosphate derivatives of electron transfer agents
KR20080085839A (ko) * 2005-12-23 2008-09-24 바이탈 헬스 사이언시즈 피티와이 리미티드 사이토킨 조절 특성을 가진 화합물
JP5313868B2 (ja) 2007-03-02 2013-10-09 テイカ製薬株式会社 経皮吸収医薬組成物、医薬組成物貯蔵ユニットおよびこれを利用する経皮吸収製剤
US9511016B2 (en) * 2007-06-12 2016-12-06 Epicentrx, Inc. Topical composition for treating pain
US8354116B2 (en) * 2007-06-18 2013-01-15 Biochemics, Inc. Bifunctional synthetic molecules
US8784872B2 (en) 2007-11-19 2014-07-22 Comgenrx, Inc. Formulation for decreasing tobacco, alcohol, drug or food consumption
US20090130048A1 (en) * 2007-11-19 2009-05-21 Oronsky Bryan Todd Topical Composition for Treating Pain
WO2009158667A2 (en) * 2008-06-27 2009-12-30 Comgenrx, Inc. Povidone compositions for wound healing
US10849981B2 (en) 2009-07-02 2020-12-01 KemPham, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
UA102916C2 (uk) * 2009-07-02 2013-08-27 Кемфарм, Інк. Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань
AU2010266209B2 (en) * 2009-07-02 2013-09-26 Kempharm, Inc. Phenylethanoic acid, phenylpropanoic acid and phenylpropenoic acid conjugates and prodrugs of hydrocodone, methods of making and use thereof
WO2011094814A1 (en) 2010-02-05 2011-08-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
MX2012011355A (es) 2010-03-30 2012-11-30 Phosphagenics Ltd Parche de suministro transdermico.
KR101955175B1 (ko) 2010-04-13 2019-03-06 나지브 바불 1-메틸-2'-6'-피페콜옥실리디드의 피부 약제학적 조성물 및 사용 방법
TWI590821B (zh) 2011-01-18 2017-07-11 輝瑞有限公司 固體分子分散液
US9561243B2 (en) 2011-03-15 2017-02-07 Phosphagenics Limited Composition comprising non-neutralised tocol phosphate and a vitamin A compound
EP3223819A4 (en) 2014-11-25 2018-04-25 Kempharm, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone
AU2016367708B2 (en) 2015-12-09 2022-07-14 Phosphagenics Limited Pharmaceutical formulation
KR102647670B1 (ko) 2016-12-21 2024-03-15 아베초 바이오테크놀로지 리미티드 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4673679A (en) * 1986-05-14 1987-06-16 E. I. Du Pont De Nemours And Company Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
US4908389A (en) * 1986-08-27 1990-03-13 Warner-Lambert Company Penetration enhancement system
US4940586A (en) * 1987-02-26 1990-07-10 Alza Corporation Skin permeation enhancer compositions using sucrose esters
US4879297A (en) * 1987-06-01 1989-11-07 Warner-Lambert Company Fatty acids and their small chain esters as penetration enhancers in aqueous systems
US4891377A (en) * 1988-12-02 1990-01-02 Board Of Regents Acting For And On Behalf Of University Of Michigan Transdermal delivery of the narcotic analgesics etorphine and analogs
WO1991015241A1 (en) * 1990-03-30 1991-10-17 Yasunori Morimoto Percutaneously absorbable composition of narcotic and nonnarcotic analgesics
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine

Also Published As

Publication number Publication date
DE69129861D1 (de) 1998-08-27
WO1992008459A1 (en) 1992-05-29
ZA918512B (en) 1992-08-26
JP3493434B2 (ja) 2004-02-03
NO931766D0 (no) 1993-05-14
IE913682A1 (en) 1992-05-20
AU655612B2 (en) 1995-01-05
SE9003665D0 (sv) 1990-11-16
CA2095223A1 (en) 1992-05-17
US5908846A (en) 1999-06-01
IL99905A (en) 1995-06-29
DE69129861T2 (de) 1999-04-01
DK0557385T3 (da) 1999-04-26
CA2095223C (en) 2002-12-17
EP0557385A1 (en) 1993-09-01
JPH06502422A (ja) 1994-03-17
IL99905A0 (en) 1992-08-18
FI932212A (fi) 1993-05-14
PT99513A (pt) 1992-09-30
NZ240349A (en) 1993-07-27
PT99513B (pt) 1999-04-30
ATE168560T1 (de) 1998-08-15
ES2121793T3 (es) 1998-12-16
EP0557385B1 (en) 1998-07-22
AU8938191A (en) 1992-06-11
FI932212A0 (fi) 1993-05-14

Similar Documents

Publication Publication Date Title
NO931766L (no) Topiske preparater for transdermal avlevering av forloeperlegemiddelderivater av morfin
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
ATE185548T1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
MY119403A (en) Novel compounds with analgesic effect.
RU94040387A (ru) Композиция, способствующая прекращению курения, никотиносодержащий распыляемый раствор, способ снижения потребности в курении табака, способ замены курения табака
EE9800223A (et) Fenantridiinid, neid sisaldavad ravimid ja nende kasutamine
GB2365772A (en) Factor
MD960330A (ro) Compuşi nepeptidilici, compoziţie farmaceutică pe baza acestora, metodă de tratament
GR1001503B (el) Μέ?οδος δια την παρασκευή φαρμακευτικών ενώσεων αι οποίαι περιέχουν ως δραστική ουσία καρβονικά οξέα τα οποία περιέχουν ?είον κα?ώς και η χρησιμοποίησις αυτών δια την καταπολέμησιν των ρετροιών.
AU2291097A (en) Novel phenanthridines substituted in the 6 position
FR2675997B1 (fr) Composition topique anti radicaux libres a base de superoxyde-dismutase et d'un derive phosphonique.
IE873125L (en) Benzimidazole derivatives
DE69731882D1 (de) Transdermal verabreichtes dextromethorphan als hustenmittel
BR0009524A (pt) Uso de um composto, e, composição farmacêutica ou veterinaria
RS49599B (sr) Upotreba inhibitora h+, k+-atp-aze i glukokortikoida i farmaceutska formulacija
AU8332791A (en) Oral pharmaceutical compositions containing melatonin
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
PH27567A (en) Topical compositions
DK0669826T3 (da) (-)-Metrifonatholdigt lægemiddel
ES2097816T5 (es) Producto y su uso para el tratamiento de estados catabolicos que comprende ifg-1 autentico y cantidades hipocaloricas de nutrientes.
IL98200A0 (en) Pharmaceutical composition containing a derivative of substituted-l-valyl-l-prolinamide
YU71293A (sh) Transdermalni terapijski sistem za davanje fizostigmina na koži i postupak za njegovu izradu
KR900017599A (ko) 종양 치료용 약학 조성물
ATE102934T1 (de) Fluorierte flavon-essigsaeure.
DE69428276D1 (de) Insulinähnlicher wachstumfaktor ii als antitumormittel